Physician profile
Drew D Schnyder
NPI 1659402782
$7,019.15
in general payments reported to CMS, 2019-2025
48 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $1,340 · 2021: $732 · 2022: $1,292 · 2023: $1,186 · 2024: $557 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Education: $37.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.26 |
| Education | $37.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.39 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $748.79 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $723.24 | 2019-2025 | |
| Novo Nordisk INC | $502.64 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $435.89 | 2019-2025 | Farxiga |
| Amgen INC. | $340.09 | 2019-2024 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $294.73 | 2019-2023 | |
| Allergan, INC. | $287.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $280.72 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $252.67 | 2019-2023 | Trintellix |
| Eisai INC. | $226.61 | 2020-2025 | |
| Preventric Diagnostics, INC. | $221.70 | 2022 | |
| Astellas Pharma US INC | $191.74 | 2019-2023 | Veozah |
| Harmony Biosciences LLC | $189.07 | 2023-2024 | Wakix |
| Phathom Pharmaceuticals, INC. | $162.48 | 2024 | Voquezna |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $129.79 | 2020 | |
| Exact Sciences Corporation | $129.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.11 | 2020-2023 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.46 | 2020-2022 | |
| Abbott Laboratories | $90.56 | 2019-2024 | Octrode, Proclaim |
| Glaxosmithkline, LLC. | $71.79 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $70.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $57.97 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $48.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.44 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $43.15 | 2022-2023 | Quviviq |
| Edwards Lifesciences Corporation | $36.48 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $32.80 | 2025 | Rexulti |
| Inari Medical, INC. | $29.88 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insulet Corporation | $29.09 | 2023 | Omnipod |
| Verona Pharma, INC. | $26.06 | 2025 | Ohtuvayre |
| Dexcom, INC. | $24.88 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $21.70 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $21.63 | 2025 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $20.16 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.18 | 2022 | |
| Nevro Corp. | $18.05 | 2022 | |
| Mylan Specialty L.P. | $17.95 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.68 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.32 | 2025 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $16.20 | 2020 | |
| Krystal Biotech INC | $15.96 | 2023 | Vyjuvek |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.86 | 2025 | Caplyta |
| Medtronic, INC. | $14.84 | 2025 | Inceptiv |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.52 | 2025 | |
| Averitas Pharma INC. | $14.16 | 2023 | Qutenza |
| Ge Healthcare | $13.57 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Schnyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.